Alkermes' alixorexton has become the first drug in the orexin 2 receptor agonist class to show efficacy in phase 2 trials involving patients with both main subtypes of sleep disorder narcolepsy.
Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback